Evidence map›Paper›PMID 35666363›Full record

ArticleEJNMMI radiopharmacy and chemistry2022

Development of a multi faceted platform containing a tetrazine, fluorophore and chelator: synthesis, characterization, radiolabeling, and immuno-SPECT imaging.

Anthony W McDonagh, Brooke L McNeil, Julie Rousseau, Ryan J Roberts, Helen Merkens, Hua Yang, François Bénard, Caterina F Ramogida

Open access · goldAbstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Development of AGT-7: An InnovativePharmaceuticals (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Anthony W McDonaghDepartment of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.
Brooke L McNeilDepartment of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.
Julie RousseauDepartment of Molecular Oncology, BC Cancer, Vancouver, BC, V5Z 1L3, Canada.
Ryan J RobertsDepartment of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.
Helen MerkensDepartment of Molecular Oncology, BC Cancer, Vancouver, BC, V5Z 1L3, Canada.
Hua YangDepartment of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.
François BénardDepartment of Molecular Oncology, BC Cancer, Vancouver, BC, V5Z 1L3, Canada.
Caterina F RamogidaDepartment of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada. cfr@sfu.ca.
Simon Fraser University · CATRIUMF · CA

Funding

Natural Sciences and Engineering Research Council of Canada RGPIN-2019-07207
6 · The paper itself

Abstract

backgroundCombining optical (fluorescence) imaging with nuclear imaging has the potential to offer a powerful tool in personal health care, where nuclear imaging offers in vivo functional whole-body visualization, and the fluorescence modality may be used for image-guided tumor resection. Varying chemical strategies have been exploited to fuse both modalities into one molecular entity. When radiometals are employed in nuclear imaging, a chelator is typically inserted into the molecule to facilitate radiolabeling; the availability of the chelator further expands the potential use of these platforms for targeted radionuclide therapy if a therapeutic radiometal is employed. Herein, a novel mixed modality scaffold which contains a tetrazine (Tz)--for biomolecule conjugation, fluorophore-for optical imaging, and chelator-for radiometal incorporation, in one construct is presented. The novel platform was characterized for its fluorescence properties, radiolabeled with single-photon emission computed tomography (SPECT) isotope indium-111 (

resultsKey to the success of the platform synthesis was incorporation of a 4,4'-dicyano-BODIPY fluorophore. The route gives access to an advanced intermediate where final chelator-incorporated compounds can be easily accessed in one step prior to radiolabeling or biomolecule conjugation. The DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) conjugate was prepared, displayed good fluorescence properties, and was successfully radiolabeled with

conclusionsThe novel platform shows promise as a multi-modal probe for theranostic applications. In particular, access to an advanced synthetic intermediate where tailored chelators can be incorporated in the last step of synthesis expands the potential use of the scaffold to other radiometals. Future studies including validation of ex vivo fluorescence imaging and exploiting the pre-targeting approach available through the IEDDA reaction are warranted.

Indexed as

Actinium-225BODIPYDOTAFluorophoreIndium-111Multi-modalProbesTetrazine

Identifiers

PMID35666363
PMCPMC9170845
OpenAlexW4281610015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.